Evidence map›Paper›PMID 33824584›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial.

Jemi Galani, Hillary Mulder, Frank W Rockhold, E Hope Weissler, Iris Baumgartner, Jeffrey S Berger, Juuso I Blomster, F Gerry R Fowkes, William R Hiatt, Brian G Katona and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01732822 (A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01732822 phase3completednot on this map

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

TypeinterventionalSponsorAstraZenecaRan2012 to 2016Enrolled13,885ConditionsPeripheral Artery DiseaseArmsTicagrelor, Clopidogrel
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Understanding Study Drug Discontinuation Through EUCLID.Frontiers in cardiovascular medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 5 countries.

Jemi GalaniDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-4920-7809
Hillary MulderDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Frank W RockholdDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-3732-4765
E Hope WeisslerDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Iris BaumgartnerDepartment of Medicine, Swiss Cardiovascular Center, University of Bern, Bern, Switzerland.
Jeffrey S BergerDepartments of Medicine and Surgery, New York University School of Medicine, New York, NY, USA.
Juuso I BlomsterUniversity of Turku, Turku, Finland.
F Gerry R FowkesUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
William R HiattDivision of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA.
Brian G KatonaAstraZeneca, Gaithersburg, MD, USA.
Lars NorgrenFaculty of Medicine and Health, Örebro University, Örebro, Sweden.
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA, USA.
Jennifer K QuintRespiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-0149-4869
Manesh R PatelDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
W Schuyler JonesDepartment of Medicine, Duke University Medical Center, Durham, NC, USA.
Duke University · USAstraZeneca (United States) · USCenter for Clinical Research (United States) · USDuke Medical Center · USImperial College London · GBMeridian Clinical Research · USNew York University · USÖrebro University · SEUniversity of Bern · CHUniversity of Edinburgh · GBUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lower extremity peripheral artery disease (PAD) and suffering PAD-related morbidity and mortality. However, the effect and burden of COPD on patients with PAD is less well defined. This post hoc analysis from EUCLID aimed to analyze the risk of major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in patients with PAD and concomitant COPD compared with those without COPD, and to describe the adverse events specific to patients with COPD.

methodsEUCLID randomized 13,885 patients with symptomatic PAD to monotherapy with either ticagrelor or clopidogrel for the prevention of MACE. In this analysis, MACE, MALE, mortality, and adverse events were compared between groups with and without COPD using unadjusted and adjusted Cox proportional hazards model.

resultsOf the 13,883 patients with COPD status available at baseline, 11% (n=1538) had COPD. Patients with COPD had a higher risk of MACE (6.02 vs 4.29 events/100 patient-years; p<0.001) due to a significantly higher risk of myocardial infarction (MI) (3.55 vs 1.85 events/100 patient-years; p<0.001) when compared with patients without COPD. These risks persisted after adjustment (MACE: adjusted hazard ratio (aHR) 1.30, 95% confidence interval [CI] 1.11-1.52; p<0.001; MI: aHR 1.45, 95% CI 1.18-1.77; p<0.001). However, patients with COPD did not have an increased risk of MALE or major bleeding. Patients with COPD were more frequently hospitalized for dyspnea and pneumonia (2.66 vs 0.9 events/100 patient-years; aHR 2.77, 95% CI 2.12-3.63; p<0.001) and more frequently discontinued study drug prematurely (19.36 vs 12.54 events/100 patient-years; p<0.001; aHR 1.34, 95% CI 1.22-1.47; p<0.001).

conclusionIn patients with comorbid PAD and COPD, the risks of MACE, respiratory-related adverse events, and premature study drug discontinuation were higher when compared with patients without COPD. REGISTRATION: ClinicalTrials.gov: NCT01732822.

Indexed as

Peripheral Arterial DiseasePulmonary Disease, Chronic ObstructiveHumansMorbidityPlatelet Aggregation InhibitorsRisk FactorsTicagrelorPlatelet Aggregation InhibitorsTicagrelorchronic obstructive pulmonary diseasemajor adverse cardiovascular eventsperipheral artery disease

Identifiers

PMID33824584
PMCPMC8018572
OpenAlexW3143687257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.